A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59  years: An interim analysis in Indonesia

CONCLUSIONS: From the 3-month interim analysis, the vaccine exhibited a 65.30% efficacy at preventing COVID-19 illness with favorable safety and immunogenicity profiles.PMID:34620531 | DOI:10.1016/j.vaccine.2021.09.052

Source: Vaccine - October 8, 2021 Category: Allergy & Immunology Authors: Eddy Fadlyana Kusnandi Rusmil Rodman Tarigan Andri Reza Rahmadi Susantina Prodjosoewojo Yulia Sofiatin Citra V Khrisna Rini Mulia Sari Lilis Setyaningsih Fikrianti Surachman Novilia Sjafri Bachtiar Hadyana Sukandar Imam Megantara Chrysanti Murad Krisna Nu Source Type: research